Clinuvel receives IND status

By Kate McDonald
Thursday, 29 January, 2009

Melbourne’s Clinuvel has received investigational new drug (IND) status for its photoprotective drug afamelanotide from the US FDA.

The ruling will allow the company to begin clinical trials in the US. It received orphan drug designation from the FDA in July last year.

Afamelanotide is currently in Phase III trials for the treatment of erythropoietic protoporphyria (EPP) in Europe and Australia, amongst several other trials in UV-related skin disorders.

Related News

SEQ koala population carries immunity to retrovirus

Koalas from a population north of the Brisbane River appear to have evolved a unique genomic...

RSV immunisation program for babies slashes hospital stays

An Australian-first study has demonstrated the effectiveness of immunisation against respiratory...

A targeted treatment option for psoriasis

New research from MedUni Vienna paves the way for the development of a therapy that not only...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd